Stroma Biosciences is a spinout company founded by Dr Ingo Ringshausen and Dr Eugene Park from the Department of Haematology. It is working on the development of therapeutics targeting stroma-intrinsic mechanisms responsible for environment-mediated drug resistance and immune modulation in cancer and autoimmune disorders.
Stroma Biosciences has been selected as one of four start-up companies taking part in the Accelerate@Babraham Start-up Programme. As part of the programme, Stroma Biosciences have secured five months access to Accelerate@Babraham’s bio-incubator facilities, including use of fully equipped laboratory space and flexible workspaces. The company also receives £10,000 of funding, personal mentoring and access to the Babraham Research Campus’ networks.